GS-6620

**GS-6620**
系统（IUPAC）命名名称
	[(2R,3R,4R,5R)-5-(4-Aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-4-hydroxy-4-methyl-2-[[[[(2S)-1-oxo-1-propan-2-yloxypropan-2-yl]amino]-phenoxyphosphoryl]oxymethyl]oxolan-3-yl] 2-methylpropanoate
临床数据
商品名	GS-6620
合法状态
合法状态	US: 研究性新药 ;
识别信息
CAS注册号	1350735-70-4
PubChem	CID 58059494
ChemSpider	31141332
UNII	WD5DUG7X38
ChEMBL	CHEMBL3120792
化学信息
化学式	C29H37N6O9P
摩尔质量	644.6
	SMILES C[C@@H](C(=O)OC(C)C)NP(=O)(OC[C@@H]1[C@H]([C@@]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)(C)O)OC(=O)C(C)C)OC4=CC=CC=C4; ;
	InChI InChI=1S/C29H37N6O9P/c1-17(2)26(36)42-24-22(43-29(15-30,28(24,6)38)23-13-12-21-25(31)32-16-33-35(21)23)14-40-45(39,44-20-10-8-7-9-11-20)34-19(5)27(37)41-18(3)4/h7-13,16-19,22,24,38H,14H2,1-6H3,(H,34,39)(H2,31,32,33)/t19-,22+,24+,28+,29-,45?/m0/s1; Key:YAAQYJCOIFNMKX-CVANIGNKSA-N;

GS-6620是一种核苷酸类的抗病毒药物，被开发用于治疗丙型肝炎。尽管它在早期测试中显示出有效的抗病毒作用^[1]^[2]，但由于它在肠道中的吸收率低且效果不稳定（无法预测血液中的浓度），未能成功制成口服剂。^[3]^[4]目前进行的研究主要针对其它疾病（如埃博拉出血热）^[5]^[6]的治疗。

参考文献

↑ Cho A, Zhang L, Xu J, Lee R, Butler T, Metobo S, et al. Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients. Journal of Medicinal Chemistry. March 2014, 57 (5): 1812–25. PMID 23547794. doi:10.1021/jm400201a.
↑ Feng JY, Cheng G, Perry J, Barauskas O, Xu Y, Fenaux M, et al. Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug. Antimicrobial Agents and Chemotherapy. 2014, 58 (4): 1930–42. PMC 4023746 . PMID 24419349. doi:10.1128/AAC.02351-13.
↑ Murakami E, Wang T, Babusis D, Lepist EI, Sauer D, Park Y, et al. Metabolism and pharmacokinetics of the anti-hepatitis C virus nucleotide prodrug GS-6620. Antimicrobial Agents and Chemotherapy. 2014, 58 (4): 1943–51. PMC 4023801 . PMID 24419340. doi:10.1128/AAC.02350-13.
↑ Gentile I, Coppola N, Buonomo AR, Zappulo E, Borgia G. Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Expert Opinion on Investigational Drugs. September 2014, 23 (9): 1211–23. PMID 24848437. doi:10.1517/13543784.2014.921680.
↑ De Clercq E. C-Nucleosides To Be Revisited. Journal of Medicinal Chemistry. March 2016, 59 (6): 2301–11. PMID 26513594. doi:10.1021/acs.jmedchem.5b01157.
↑ De Clercq E. New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections. Chemistry, an Asian Journal. November 2019, 14 (22): 3962–3968. PMID 31389664. doi:10.1002/asia.201900841.

[1] Cho A, Zhang L, Xu J, Lee R, Butler T, Metobo S, et al. Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients. Journal of Medicinal Chemistry. March 2014, 57 (5): 1812–25. PMID 23547794. doi:10.1021/jm400201a.

[2] Feng JY, Cheng G, Perry J, Barauskas O, Xu Y, Fenaux M, et al. Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug. Antimicrobial Agents and Chemotherapy. 2014, 58 (4): 1930–42. PMC 4023746 . PMID 24419349. doi:10.1128/AAC.02351-13.

[3] Murakami E, Wang T, Babusis D, Lepist EI, Sauer D, Park Y, et al. Metabolism and pharmacokinetics of the anti-hepatitis C virus nucleotide prodrug GS-6620. Antimicrobial Agents and Chemotherapy. 2014, 58 (4): 1943–51. PMC 4023801 . PMID 24419340. doi:10.1128/AAC.02350-13.

[4] Gentile I, Coppola N, Buonomo AR, Zappulo E, Borgia G. Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Expert Opinion on Investigational Drugs. September 2014, 23 (9): 1211–23. PMID 24848437. doi:10.1517/13543784.2014.921680.

[5] De Clercq E. C-Nucleosides To Be Revisited. Journal of Medicinal Chemistry. March 2016, 59 (6): 2301–11. PMID 26513594. doi:10.1021/acs.jmedchem.5b01157.

[6] De Clercq E. New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections. Chemistry, an Asian Journal. November 2019, 14 (22): 3962–3968. PMID 31389664. doi:10.1002/asia.201900841.

[1]

[2]

[3]

[4]

[5]

[6]